CSI Market
Sign In | Register

Neurocrine Biosciences Inc (NBIX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NBIX Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Neurocrine Biosciences Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income342.30
Depreciation & amortization15.60
Amortization of Other Assets16.50
Increase (Decrease) in Deferred Revenue0.00
Impairment of Leasehold0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories2.20
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal28.60
Share-based Compensation122.20
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gains Losses On Sales Of Assets-
Other Than Temporary Impairment Losses Auction Rate Securities-
Cease Use Expense-
Equity Securities Fv Ni Unrealized Gain Loss-25.30
Charges Associated With Convertible Senior Notes-
Operating Lease Right Of Use Asset Amortization Expense2.70
Income taxes0.00
Gain (Loss) on Sale of Investments0.00
Accounts Receivable225.90
Increase (Decrease) in Accounts Payable and Accrued Liabilities-22.80
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-47.40
Other Noncash Income (Expense)0.00
Other net1.60
Payments for (Proceeds from) Other Operating Activities-402.50
Discontinued operations0.00
Net Cash flow from Operating Activities282.20
Investing Activities
Capital Expenditures-16.90
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities2,527.50
Payments to Acquire Available-for-sale Securities, Debt-856.90
Real Estate Investments0.00
Payments For Investment In Equity Securities-
Payments To Acquire Equity Securities Fv Ni-
Payments to Acquire Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-2,358.50
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses63.20
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-641.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-6.70
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock42.40
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-58.40
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-22.70
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow265.30
Total Cash Flow-382.10
4 historic quarters locked

Sign in to unlock the full Neurocrine Biosciences Inc cash flow history.

Sign In Create Free Account

About Neurocrine Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000914475-26-000037

Figures are derived from filed reports and may be restated. Historical data is subject to revision.